Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Just For You
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Submitted by Jeffrey Neal Johnson. Publication Date: 4/7/2026. In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking. Abbott Laboratories’ stock price recently hit a 52-week low, closing just above $100 in the last trading days of March. The sharp decline has many investors asking whether the foundation of this industry leader is cracking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Key Points
Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment. Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders. Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion. - Special Report: Elon Musk: This Could Turn $100 into $100,000
A closer look at Abbott Laboratories' current situation reveals a potential disconnect between market sentiment and operational reality. The key question for long-term investors is whether the market’s pessimism is justified or has created a meaningful value opportunity. Separating the Signal From the NoiseAbbott’s recent drop is driven by two distinct pressures. The first is an internal headwind in its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, primarily due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been candid about the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026 intended to reignite volume growth, with a return to growth expected in the second half of the year. The second pressure is external and broader: a market rotation. As investor optimism grows, capital has shifted away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector. That broader trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a short-term recovery, Abbott’s core businesses remain strong—led by its largest and most profitable division, Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter, and helps offset the isolated weakness in nutrition.
Medical Devices: The Medical Devices engine is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. The product line, which lets users track glucose levels without routine fingersticks, generated over $7.5 billion in sales in 2025 and is a primary driver of Abbott's sustained success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular care. Its Electrophysiology business grew at a double-digit rate, and its Structural Heart business posted strong organic growth of 8.7%. This strength stems from best-in-class products such as MitraClip and TriClip—minimally invasive solutions for valve repair—and a pipeline that includes the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also taking strategic steps to secure future growth, notably through the acquisition of Exact Sciences. Exact Sciences, known for its non-invasive colon cancer test Cologuard, would add a high-growth cancer diagnostics franchise to Abbott’s portfolio. The deal immediately positions Abbott in the expanding, multi-billion-dollar cancer diagnostics market, creating a new growth vertical that could contribute material revenue for years. Professional analysts appear to share this constructive view. Wall Street maintains a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47—implying more than 30% upside from current levels. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is a compelling feature. Abbott is a member of the S&P 500 Dividend Kings, a select group of companies that have raised their dividend for at least 50 consecutive years. That track record reflects a deep commitment to returning capital to shareholders through market cycles. The recent drop in Abbott’s stock price has a practical benefit for new investors: a higher dividend yield. At current levels, Abbott yields roughly 2.5%, letting investors lock in a stronger income rate from a historically reliable payer. The dividend also appears well supported. Abbott’s payout ratio is about 68% of earnings, and the dividend represents roughly 37% of cash flow—indicating the company generates more than enough cash to cover the payout and preserves room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from its operating reality. Temporary headwinds in a single division and broader sector rotations have depressed the stock price, but Abbott's fundamental growth engines—especially Medical Devices and Diabetes Care—are accelerating. Its dividend remains a reliable income source, and strategic catalysts such as the Exact Sciences acquisition could drive meaningful future growth. For investors with a long-term horizon, the current valuation suggests a gap between price and intrinsic value that warrants consideration. |
